
Novo Nordisk's obesity business and the insulin sales prospects in China could take center stage when the Danish pharmaceutical company releases its quarterly report Wednesday morning.
Some of the suspense surrounding the release has been reduced as Novo Nordisk upgraded its financial guidance on Friday last week, mentioning strong sales of type-2 diabetes drug Ozempic and weight loss drug sales in the US.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app